ADA Scientific Sessions 2026 Abstract
Medical Spending Before and After GLP-1RA Initiation among Commercially Insured Adults Aged 18–64 Years with Type 2 Diabetes
Study in peopleInterventions
Papers by Kai Bullard
9 results
- ADA Scientific Sessions 2026 Abstract
Socioeconomic Differences in Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors among Eligible U.S. Adults with Type 2 Diabetes
Study in peoplePopulations - ADA Scientific Sessions 2026 Abstract
Impact of GLP-1RA Initiation on Medical Expenditures in Medicare Beneficiaries with Type 2 Diabetes
Study in peopleInterventions - ADA Scientific Sessions 2025 Abstract
Trends in Diagnosed Diabetes Prevalence across Anthropometric Measurements in the United States, 2001–2023
Study in peoplePopulations
- ADA Scientific Sessions 2025 Abstract
Disparities in New Glucose-Lowering Drug Spending in U.S. Adults with Type 2 Diabetes (T2D), 2018–2022
Study in peoplePopulations - ADA Scientific Sessions 2025 Abstract
Long-Term Cost-Effectiveness of Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Preventing Type 2 Diabetes (T2D) in U.S. Adults with Prediabetes and Obesity—A Simulation Study
Computational studyInterventions - ADA Scientific Sessions 2025 Abstract
Trends in Comorbidities among U.S. Adults with Undiagnosed or Newly Diagnosed Diabetes, NHANES 2001–2020
Study in peoplePopulations - ADA Scientific Sessions 2025 Abstract
Changes in Medical Expenditures Associated with GLP-1RA Initiation in Medicare Beneficiaries with Type 2 Diabetes
Study in peopleInterventions